Darabioscienceincis A Clinical Stage Biopharmaceutical Company Focused On Advancing Innovative Products For Women S Healththe Company Aims To Address Unmet Needs In Areas Such As Contraceptionsexual Healthpelvic Painfertilityinfectious Diseasesvaginal Healthand Menopauseunder The Leadership Of President And Ceo Sabrina Martucci Johnsondarais Committed To Developing Evidence Based Treatment Solutions The Company Identifiesdevelopsand Markets Products Designed To Improve Women S Healthits First Fda Approved Productxaciatoa Cclindamycin Phosphatevaginal Gel 2 Is Indicated For The Treatment Of Bacterial Vaginosis In Female Patients Aged 12 And Olderadditionallydarais Developing Ovaprenea Potential First In Category Candidate Currently In Clinical Developmentdarabioscience Is Listed On The Nasdaq Under The Ticker Symbol Dare And Actively Engages With Investors To Share Updates On Its Progress And Financial Performance
